Skip to main content
Top
Published in: Radiation Oncology 1/2019

Open Access 01-12-2019 | Metastasis | Research

Postoperative adjuvant radiation improves local control in surgically treated FIGO stage I-II small cell carcinoma of the cervix

Authors: Ting Shen, Yan-hui Jiang, Yao-yao Zou, Fang-fang Qiu, Xing-sheng Qiu, Kai-yun You

Published in: Radiation Oncology | Issue 1/2019

Login to get access

Abstract

Objective

To determine the prognostic effect of adjuvant radiation and clinicopathological variables in surgically treated patients with small cell carcinoma of the cervix (SCCC).

Methods

Clinical data of SCCC patients with International Federation of Gynaecology and Obstetrics (FIGO) stage I-II underwent radical surgery from May 2000 to August 2014 at Sun Yat-sen Memorial Hospital were retrospectively reviewed. Forty-three patients with SCCC were included to this study. Chi-square test or Fisher’s exact test, Student’s t test or Mann–Whitney U test, Kaplan–Meier method and multivariate analysis of Cox proportional hazards regression were used for statistical analysis. P < 0.05 was considered to be statistically significant.

Results

Among 43 patients (median age, 49 years old) recruited, 25(58.1%) had stage I, 18(41.9%) had stage II disease. The 5-year overall survival (OS) rate was 39.54%, and the 5-year disease free survival (DFS) was 27.91%. Distant metastasis was the main cause of treatment failure (71.9%). Patients with adjuvant chemoradiation displayed lower rate of local recurrence than those with adjuvant chemotherapy (10.7% vs 60.0%, P < 0.0001). Multivariable analysis identified lymph node metastasis as a significant prognostic factor for both DFS and OS (P = 0.001, 0.004 respectively). Age was also an independent predictor of OS (P = 0.004). Adjuvant radiation appeared to significantly improve DFS (HR = 0.383, 95% CI, 0.185–0.791), but not OS.

Conclusions

Adjuvant radiotherapy could improve the local control and prolong DFS in surgically treated SCCC. However, a large prospective clinical trial is needed to confirm this.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hoskins PJ, et al. Small-cell carcinoma of the cervix: fourteen years of experience at a single institution using a combined-modality regimen of involved-field irradiation and platinum-based combination chemotherapy. J Clin Oncol. 2003;21(18):3495–501.CrossRef Hoskins PJ, et al. Small-cell carcinoma of the cervix: fourteen years of experience at a single institution using a combined-modality regimen of involved-field irradiation and platinum-based combination chemotherapy. J Clin Oncol. 2003;21(18):3495–501.CrossRef
2.
go back to reference Cohen JG, et al. Small cell carcinoma of the cervix: treatment and survival outcomes of 188 patients. Am J Obstet Gynecol. 2010;203(4):347.e1–6.CrossRef Cohen JG, et al. Small cell carcinoma of the cervix: treatment and survival outcomes of 188 patients. Am J Obstet Gynecol. 2010;203(4):347.e1–6.CrossRef
3.
go back to reference Chen J, Macdonald OK, Gaffney DK. Incidence, mortality, and prognostic factors of small cell carcinoma of the cervix. Obstet Gynecol. 2008;111(6):1394–402.CrossRef Chen J, Macdonald OK, Gaffney DK. Incidence, mortality, and prognostic factors of small cell carcinoma of the cervix. Obstet Gynecol. 2008;111(6):1394–402.CrossRef
4.
go back to reference McCusker ME, et al. Endocrine tumors of the uterine cervix: incidence, demographics, and survival with comparison to squamous cell carcinoma. Gynecol Oncol. 2003;88(3):333–9.CrossRef McCusker ME, et al. Endocrine tumors of the uterine cervix: incidence, demographics, and survival with comparison to squamous cell carcinoma. Gynecol Oncol. 2003;88(3):333–9.CrossRef
5.
go back to reference Satoh T, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix. Int J Gynecol Cancer. 2014;24(Supp 3):S102–8.CrossRef Satoh T, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix. Int J Gynecol Cancer. 2014;24(Supp 3):S102–8.CrossRef
6.
go back to reference Viswanathan AN, et al. Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence. Gynecol Oncol. 2004;93(1):27–33.CrossRef Viswanathan AN, et al. Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence. Gynecol Oncol. 2004;93(1):27–33.CrossRef
7.
go back to reference Crowder S, Tuller E. Small cell carcinoma of the female genital tract. Semin Oncol. 2007;34(1):57–63.CrossRef Crowder S, Tuller E. Small cell carcinoma of the female genital tract. Semin Oncol. 2007;34(1):57–63.CrossRef
8.
go back to reference Pei X, et al. Cycles of cisplatin and etoposide affect treatment outcomes in patients with FIGO stage I-II small cell neuroendocrine carcinoma of the cervix. Gynecol Oncol. 2017;147(3):589–96.CrossRef Pei X, et al. Cycles of cisplatin and etoposide affect treatment outcomes in patients with FIGO stage I-II small cell neuroendocrine carcinoma of the cervix. Gynecol Oncol. 2017;147(3):589–96.CrossRef
9.
go back to reference Marth C, et al. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv72–83.CrossRef Marth C, et al. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv72–83.CrossRef
10.
go back to reference Angiolo G, Silvestro C, Giovanni A. Neuroendrocrine tumors of the uterine cervix: a therapeutic challenge for gynecologic oncologists. Gynecol Oncol. 2016;144(3):637–46. Angiolo G, Silvestro C, Giovanni A. Neuroendrocrine tumors of the uterine cervix: a therapeutic challenge for gynecologic oncologists. Gynecol Oncol. 2016;144(3):637–46.
11.
go back to reference Gardner GJ, Reidy-Lagunes D, Gehrig PA. Neuroendocrine tumors of the gynecologic tract: a Society of Gynecologic Oncology (SGO) clinical document. Gynecol Oncol. 2011;122(1):190–8.CrossRef Gardner GJ, Reidy-Lagunes D, Gehrig PA. Neuroendocrine tumors of the gynecologic tract: a Society of Gynecologic Oncology (SGO) clinical document. Gynecol Oncol. 2011;122(1):190–8.CrossRef
12.
go back to reference Boruta DM, et al. Multimodality therapy in early-stage neuroendocrine carcinoma of the uterine cervix. Gynecol Oncol. 2001;81(1):82–7.CrossRef Boruta DM, et al. Multimodality therapy in early-stage neuroendocrine carcinoma of the uterine cervix. Gynecol Oncol. 2001;81(1):82–7.CrossRef
13.
go back to reference Chang TC, et al. Prognostic factors in surgically treated small cell cervical carcinoma followed by adjuvant chemotherapy. Cancer. 1998;83(4):712–8.CrossRef Chang TC, et al. Prognostic factors in surgically treated small cell cervical carcinoma followed by adjuvant chemotherapy. Cancer. 1998;83(4):712–8.CrossRef
14.
go back to reference Chan JK, Loizzi V, Burger RA. Prognostic Factors in Neuroendocrine Small Cell Cervical Carcinoma. Cancer. 2003;3(Volume 97):568–74.CrossRef Chan JK, Loizzi V, Burger RA. Prognostic Factors in Neuroendocrine Small Cell Cervical Carcinoma. Cancer. 2003;3(Volume 97):568–74.CrossRef
15.
go back to reference Lee JM, et al. Prognostic factors in FIGO stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study. Ann Oncol. 2008;19(2):321–6.CrossRef Lee JM, et al. Prognostic factors in FIGO stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study. Ann Oncol. 2008;19(2):321–6.CrossRef
16.
go back to reference Ishikawa M, et al. Prognostic factors and optimal therapy for stages I–II neuroendocrine carcinomas of the uterine cervix: a multi-center retrospective study. Gynecol Oncol. 2018;148(1):139–46.CrossRef Ishikawa M, et al. Prognostic factors and optimal therapy for stages I–II neuroendocrine carcinomas of the uterine cervix: a multi-center retrospective study. Gynecol Oncol. 2018;148(1):139–46.CrossRef
17.
go back to reference Wang K, et al. Primary treatment and prognostic factors of small cell neuroendocrine carcinoma of the uterine cervix: a Taiwanese gynecologic oncology group study. Eur J Cancer. 2012;48(10):1484–94.CrossRef Wang K, et al. Primary treatment and prognostic factors of small cell neuroendocrine carcinoma of the uterine cervix: a Taiwanese gynecologic oncology group study. Eur J Cancer. 2012;48(10):1484–94.CrossRef
Metadata
Title
Postoperative adjuvant radiation improves local control in surgically treated FIGO stage I-II small cell carcinoma of the cervix
Authors
Ting Shen
Yan-hui Jiang
Yao-yao Zou
Fang-fang Qiu
Xing-sheng Qiu
Kai-yun You
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2019
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-019-1409-7

Other articles of this Issue 1/2019

Radiation Oncology 1/2019 Go to the issue